Company Legal Name
Latest Valuation
Founded Year
Headquarter
BillionToOne develops advanced genetic testing technology that enables prenatal screening and cancer therapy selection through blood sample analysis. Founded in 2016 and headquartered in Menlo Park, California, the company has established itself as a significant player in the precision medicine sector by offering non-invasive diagnostic solutions that provide critical genetic insights for healthcare providers and patients. The company achieved unicorn status with a $1 billion valuation, reflecting strong investor confidence in its innovative approach to genetic testing. BillionToOne continues to focus on expanding its diagnostic capabilities and advancing personalized medicine through its proprietary blood-based testing platform.
Revenue & Revenue Growth Share
Revenue
Revenue Growth
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.





